- Home
- ALT vs KOD Comparison
ALT vs KOD Comparison
Compare ALT & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALT
- KOD
- Stock Information
- Founded
- ALT 1997
- KOD 2009
- Country
- ALT United States
- KOD United States
- Employees
- ALT N/A
- KOD N/A
- Industry
- ALT Biotechnology: Pharmaceutical Preparations
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALT Health Care
- KOD Health Care
- Exchange
- ALT Nasdaq
- KOD Nasdaq
- Market Cap
- ALT 472.3M
- KOD 454.7M
- IPO Year
- ALT N/A
- KOD 2018
- Fundamental
- Price
- ALT $5.28
- KOD $3.42
- Analyst Decision
- ALT Strong Buy
- KOD Hold
- Analyst Count
- ALT 8
- KOD 4
- Target Price
- ALT $20.83
- KOD $8.00
- AVG Volume (30 Days)
- ALT 2.5M
- KOD 305.9K
- Earning Date
- ALT 05-08-2025
- KOD 03-27-2025
- Dividend Yield
- ALT N/A
- KOD N/A
- EPS Growth
- ALT N/A
- KOD N/A
- EPS
- ALT N/A
- KOD N/A
- Revenue
- ALT $20,000.00
- KOD N/A
- Revenue This Year
- ALT N/A
- KOD N/A
- Revenue Next Year
- ALT N/A
- KOD N/A
- P/E Ratio
- ALT N/A
- KOD N/A
- Revenue Growth
- ALT N/A
- KOD N/A
- 52 Week Low
- ALT $5.15
- KOD $2.19
- 52 Week High
- ALT $11.50
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- ALT 38.48
- KOD 32.08
- Support Level
- ALT $5.15
- KOD $3.59
- Resistance Level
- ALT $6.09
- KOD $3.89
- Average True Range (ATR)
- ALT 0.42
- KOD 0.32
- MACD
- ALT -0.05
- KOD 0.08
- Stochastic Oscillator
- ALT 24.54
- KOD 30.56
About ALT Altimmune Inc.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.